Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGaming Realms Regulatory News (GMR)

Share Price Information for Gaming Realms (GMR)

Share Price is delayed by 15 minutes
Get Live Data
33.40    1.20 (3.73%)
Bid:
31.60
Ask:
32.80
Spread: 1.20 (3.797%)
Market Cap: £91.40m
GMR Live PriceLast checked at - London Stock Exchange

Intraday Gaming Realms Share Chart

AGM Statement

27 Mar 2012 07:00

RNS Number : 1144A
Pursuit Dynamics PLC
27 March 2012
 



27 March 2012

 

AGM Statement

 

At 11.00am today, Andy Quinn, the Chairman of Pursuit Dynamics plc ("PDX" or the "Company") will deliver the following statement at the Company's Annual General Meeting.

"On 22 February 2012, PDX published a prospectus in connection with its successful Rights Issue and Placing which, among other things, provided an update on developments within the business. The business continues to make progress and the Board's view of the prospects for the business remains as it was at the time of publication of the prospectus.

With the benefit of receipt of the proceeds from the Rights Issue and Placing, the Company's cash balances at 23 March 2012 were £9.8 million. The Company's cost cutting programme has reduced headcount by around 25% and reduced expenditure from a run rate of approximately £1.2 million per month in December 2011 to £1 million per month currently and will reduce it to £750,000 per month later in this financial year.

Industrial Licensing

The Company's exclusive Joint Development Agreement with Procter and Gamble ("P&G") was extended to the end of March 2012. Testing is at an advanced stage and P&G is now in the process of data discovery and translating technical performance to model commercial benefits across the first business unit. We hope to progress to a commercial agreement although there can be no certainty as to whether and when that might be achieved. An announcement will be made of developments in our discussions as appropriate.

Bioenergy

Our near-term focus in this Line of Business ("LOB") is to establish ourselves successfully in the corn to ethanol market, largely located in the US. The 'Early Adopter' model that we pursued during 2011 has achieved important market penetration, proved that the system produces economic benefits for clients and given us a valuable understanding of the impact of our technology across a variety of installation configurations. The challenges being addressed by the Company are threefold: the achievement of auditable results that confirm the financial benefits our customers have received with the ERS; the establishment of commercial agreements which enable commencement of revenue flow on a sustained basis, and; the optimisation and measurement of plant performance utilising proven scientific tools, which we currently expect to complete in the first six months of calendar year 2012. Our expectations for the current year envisage 625mgpa of capacity installed, or in the final stages of installation, by the end of September 2012. 

Brewing, Food & Beverage

Hagen Gehringer, who is responsible for our Public Health & Safety LOB, has also taken over responsibility for this LOB. The team expects to secure further sales from existing customers in both Brewing and Food. Additionally PDX hopes to exploit new opportunities in the beer mashing and cereal cooking areas although no sales have yet been achieved. We continue to discuss licensing arrangements with a number of potential partners to assist us in accelerating the marketing and commercialisation of both our brewing and food product offerings globally.

Public Health & Safety

Discussions continue across the existing and potential client base to achieve sales for our new products and from our existing projects.

Based on the work of previous years we have developed two products: the man-portable First Responder System ("FRS") and a Mobile System. The FRS prototype was tested and the first production batch is being built. We have exhibited the product and will demonstrate it in April at a major trade event. The interest from customers has been encouraging and orders are expected over the next few months. In parallel we are evaluating our distribution strategy through sales partners and dealers.

The initial Mobile System units will be available from mid May. We have received expressions of interest and we anticipate making our first sale in May. Additionally, we are now planning field tests with prospective customers over the next few months in hospitals and industrial environments.

We have completed two projects with customers in the nuclear environment, both successfully. We expect repeat revenues from these customers in this fiscal year. Furthermore we have demonstrated our ability to spray polymers and create a peelable coating for the removal of radioactive particles. We expect to generate further sales within this fiscal year.

Waste Treatment

Phase 1 (proof of concept) trials with Thames Water are about to complete and will be reviewed shortly. Phase 2 (product development) protocols, will then be determined. The key areas of assessment revolve around the pasteurisation, foodwaste and biogas processes. No significant revenues are expected from this LOB in 2012 but the Company is pleased with the progress that has been made and the potential for emergence of revenues in the medium to long term."

Further updates will be provided with the publication of the results for the half year ended March 31 2012, which we anticipate will be announced at the end of May.

 

End

 

For Further Information, please contact:

 

Pursuit Dynamics PLC

Jeremy Pelczer, Interim Chief Executive

Richard Webster, Chief Financial Officer

 

Tel: +44 (0)1480 422050

M:Communications

Elly Williamson

 

Tel: +44 (0)20 7920 2339

Cenkos Securities plc

Ian Soanes / Max Hartley

 

Tel: +44 (0)20 7397 8924

Mirabaud Securities LLP

Rory Scott

Tel: +44 (0)207 878 3360

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSESFWMFESEDD
Date   Source Headline
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
24th Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20255:25 pmRNSTotal Voting Rights
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20255:21 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.